Friday, Nov. 13, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $24.16 to $3,621,256.80.

Highlighted Stocks Traded by Insiders:

Chesapeake Lodging (CHSP) - FREE Research Report

Vicari Douglas W, who is Evp & Cfo at Chesapeake Lodging, bought 10,000 shares at $27.50 on Nov. 13, 2015. Following this transaction, the Evp & Cfo owned 312,661 shares meaning that the stake was boosted by 3.3% with the 10,000-share transaction.

The shares most recently traded at $27.62, up $0.12, or 0.43% since the insider transaction. Historical insider transactions for Chesapeake Lodging go as follows:

  • 4-Week # shares bought: 930
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 930
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 20,430
  • 24-Week # shares sold: 10,000

The average volume for Chesapeake Lodging has been 378,800 shares per day over the past 30 days. Chesapeake Lodging has a market cap of $1.7 billion and is part of the financial sector and real estate industry. Shares are down 26.28% year-to-date as of the close of trading on Friday.

Chesapeake Lodging Trust is a self-advised real estate investment trust organized in the state of Maryland in June 2009. The company focuses on investments primarily in upper-upscale hotels in major business and convention markets and premium select-service hotels in urban settings or unique locations in the United States. The stock currently has a dividend yield of 5.74%. The company has a P/E ratio of 31.3. Currently, there are 3 analysts who rate Chesapeake Lodging a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHSP - FREE

TheStreet Quant Ratings

rates Chesapeake Lodging as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Chesapeake Lodging Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

UCP (UCP) - FREE Research Report

Bogue Dustin L., who is President And Ceo at UCP, sold 40,000 shares at $7.70 on Nov. 13, 2015. Following this transaction, the President And Ceo owned 17,471 shares meaning that the stake was reduced by 69.6% with the 40,000-share transaction.

The shares most recently traded at $7.66, down $0.04, or 0.52% since the insider transaction. Historical insider transactions for UCP go as follows:

  • 24-Week # shares bought: 4,350

The average volume for UCP has been 41,500 shares per day over the past 30 days. UCP has a market cap of $63.6 million and is part of the industrial goods sector and materials & construction industry. Shares are down 25.52% year-to-date as of the close of trading on Friday.

TheStreet Recommends

UCP, Inc. operates as a homebuilder and land developer in California, Washington, North and South Carolina, and Tennessee, the United States. The company operates in two segments, Homebuilding and Land Development. Currently, there are no analysts who rate UCP a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UCP - FREE

TheStreet Quant Ratings

rates UCP as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and weak operating cash flow. Get the full

UCP Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aegerion Pharmaceuticals (AEGR) - FREE Research Report

Broadfin Healthcare Master Fund Ltd, who is 10% Owner at Aegerion Pharmaceuticals, bought 40,100 shares at $10.96 on Nov. 13, 2015. Following this transaction, the 10% Owner owned 4.0 million shares meaning that the stake was boosted by 1.01% with the 40,100-share transaction.

The shares most recently traded at $10.08, down $0.88, or 8.77% since the insider transaction. Historical insider transactions for Aegerion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,150
  • 12-Week # shares bought: 1,150
  • 24-Week # shares bought: 1,150

The average volume for Aegerion Pharmaceuticals has been 762,500 shares per day over the past 30 days. Aegerion Pharmaceuticals has a market cap of $268.8 million and is part of the health care sector and drugs industry. Shares are down 51.62% year-to-date as of the close of trading on Friday.

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. Currently, there are 2 analysts who rate Aegerion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AEGR - FREE

TheStreet Quant Ratings

rates Aegerion Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, generally high debt management risk, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Aegerion Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.